Jackie Salotti

Company: ReviR Therapeutics

Job title: Principal Scientist

Seminars:

Leveraging Lessons from Clinical Successes with RNA Splicing Modifiers & Modulators to Improve Small Molecule Drug Design 3:15 pm

With Risdiplam being the first RNA-targeting small molecule drug in the clinic, the community is investigating the vast potentials of RNA splicing modulators. As the first-in-class splicing modulator for treatment of spinal muscular atrophy, Risdiplam carved the way to exploring future indications of the chemical space for splicing modulators. How to use RNA splicing to…Read more

day: Pre-Conference Workshop Day